GHRH and ghrelin mimetics: two keys on the same pituitary lock

Meet the somatotroph — that's the cell in the anterior pituitary whose job is to secrete growth hormone. It already expects two on-signals and one off. Growth-hormone-releasing hormone, GHRH, is written by neurons in the arcuate nucleus of the hypothalamus into the portal capillaries that bathe the gland. It occupies GHRHR, a class-B G protein-coupled receptor: seven helices, Gs on the inside, cyclic AMP up. Ghrelin, written mainly in the stomach and uniquely octanoylated on serine 3 — a fat chain on one amino acid, and it's required — occupies GHS-R1a, a class-A receptor that loads Gq, raises calcium, and turns the volume of a GHRH pulse up. Somatostatin, from periventricular neurons, occupies SSTR2 and SSTR5, loads Gi, and shuts the gate. Cyril Bowers showed, in pituitary-cell and animal papers through the 1980s and 1990s, that a GHRH analogue plus a ghrelin-mimetic secretagogue releases more growth hormone than the arithmetic sum of either ligand. Two second-messenger systems, one secretory machine, one dense-core granule packed with the 191-residue four-helix bundle. That's synergy as a receptor fact. We'll walk the two locks, the messengers, the pulse-length GHRH analogue, the selective pentapeptide, and the stop signal that stays in the background.

In short. Pituitary cells that release growth hormone have two on-switches and one off-switch. Using both together makes a larger burst than adding the two signals up.

If you're holding two vials, you deserve to know which molecule is in which cake, and which question those two molecules can ask together. Next door we walk the whole growth-hormone axis: GHRH, ghrelin, somatostatin, the 191-residue ligand, hepatic IGF-1, four laboratory analogues on four microphones. The GHRH analogue without the Drug Affinity Complex is one on-switch, a tetrasubstituted twenty-nine-mer that still pulses. Ipamorelin is the other, a selective GHS-R1a pentapeptide with little of the ACTH and prolactin drag that GHRP-6 carried. This page is the pair, written at the length the synergy actually needs. It's the two receptors, the two G proteins, Bowers' additivity-plus, dipeptidyl peptidase-IV at alanine-2, the maleimide we leave off so the pulse survives, Raun's 1998 tables, Veldhuis's digital GH signal, and the reason a blend in one vial is still two named sequences. It isn't a protocol. Papers that already combined GHRH analogues and secretagogues in slices and in animals are in PubMed, with concentrations and sampling intervals. Stay here if you wanted the two locks explained as one physiological sentence.

In short. This page is about using the two pituitary on-switches together. Other pages cover each peptide on its own and the whole hormone axis around them.

CJC-1295 without DAC is tetrasubstituted GRF(1–29), often called modified GRF 1–29: D-Ala2, Gln8, Ala15, Leu27, resistant to dipeptidyl peptidase-IV, still short-acting, still a pulse. The DAC version hangs an N-ε-maleimidopropionyl group that Michael-adds to albumin cysteine 34 and turns that pulse into a multi-day flat line. Ipamorelin is Aib-His-D-2-Nal-D-Phe-Lys-NH2, the GHS-R1a agonist Raun, Hansen, Nielsen, Heinig, Andersen, Thøgersen, Ankersen and Madsen designed so that ACTH and prolactin would stay quiet at growth-hormone-effective doses. Using both is occupying the two physiological inputs the somatotroph already knows how to read. It isn't a blended drink, and it isn't a recipe printed on a stopper. Sequence identity is the honest link between a catalogue vial and a paper. HPLC and mass spectrometry are how you know which chain, or which two chains, went into the well. A certificate that can't show two main peaks and two masses, when two ligands were claimed, hasn't yet named the experiment. The rest of this piece is the biochemistry you'd want on the bench before you design the two-receptor assay you actually have the controls for.

In short. One analogue is a short GHRH copy that still comes in bursts. The other is a clean ghrelin-receptor pentapeptide. Together they occupy the two natural on-switches.

The somatotroph reads a ratio in portal blood, a cyclic-AMP increment from GHRH, a calcium current from GHS-R1a, a Gi brake from somatostatin, and a readily-releasable pool of dense-core granules. Johannes Veldhuis spent a career showing that the product of that ratio is a digital signal: night-time bursts, a low interpulse baseline, suppression by hyperglycaemia, amplification by fasting. A GHRH analogue is a probe at the first of the two on-receptors. A secretagogue analogue is a probe at the second. How long each sits there, and how cleanly, decides whether the somatotroph still sees peaks and troughs with an isolated G-protein increment, or whether it sees a plateau plus a stress-axis sentence that the IGF-1 draw can't unpick. Four amino acids decide the GHRH clock. Five residues and a pair of D-aromatics decide the secretagogue census. A maleimide on a lysine decides whether the first clock is still a clock. That's the argument for occupying both locks as two named questions, with the papers you'd expect to have on the desk. The figure is a late readout. The receptors are early, and they're where the story actually lives.

In short. These cells release growth hormone in bursts, mostly at night. How long each analogue lasts, and how cleanly it sits, decides whether those bursts still have quiet gaps.

The hypothalamus writes growth-hormone-releasing hormone into the portal capillaries that bathe the anterior pituitary, a millimetre or two away. The neurons sit mainly in the arcuate nucleus. The peptide is forty-four residues in the human, processed from a larger precursor, amidated at the C-terminus. Guillemin, Schally, Rivier, Vale, Thorner and colleagues isolated it from tumour and hypothalamic extracts in the early 1980s after a decade of false starts and a graveyard of putative GRFs that didn't survive a pituitary-cell assay. Science, 1982, Guillemin's group; Nature, 1982, Vale and Rivier's. Those papers turned a physiological inference — something from the hypothalamus releases GH — into a sequence you could synthesise, and that's still a thrilling moment if you sit with it. The first twenty-nine residues, GRF(1–29)-NH2, occupy GHRHR with full efficacy. That truncation is the backbone of every laboratory GHRH analogue that matters, including the tetrasubstituted peptide sold as CJC-1295 without DAC. Length isn't decoration. The receptor's extracellular domain reads a defined face of the peptide, and chemists have known which end does the activating work since the isolation papers were still warm. A five-residue ghrelin-receptor agonist can't be redescribed as a short GHRH. Two locks. Two ligand lengths.

In short. GHRH is a 44-amino-acid message from the brain to the pituitary. The first twenty-nine amino acids already do the full job at its receptor.

Somatostatin is the stop, and if you occupy two on-receptors without naming it you've described two thirds of the hypothalamic sentence. Brazeau, Vale, Guillemin, Science 1973: a fourteen-residue cyclic peptide from hypothalamic extracts that inhibited growth-hormone release in pituitary cells, named for that job before its wider life as a gut and pancreatic hormone was mapped. A twenty-eight-residue N-terminally extended form exists and isn't a footnote in some tissues. On the somatotroph the relevant receptors are mainly SSTR2 and SSTR5, class-A GPCRs coupled to Gi. Adenylyl cyclase falls. Cyclic AMP falls. The L-type calcium current that GHRH had opened is opposed. Granule fusion slows. Somatostatin tone is high between pulses and drops as a pulse is allowed through. The go is therefore a double event: GHRH up and somatostatin down, arriving as a ratio, with ghrelin as a volume knob on that ratio rather than as a third independent slider. An analogue at GHRHR, and another at GHS-R1a, still have to live with that ratio. They can't repeal Gi. They can only raise the Gs side and the Gq side of a contest that the stop peptide is still fighting.

In short. Somatostatin is the brain's stop signal for growth hormone. A pulse is really a ratio of go to stop, with ghrelin turning the volume up.

Portal blood is the medium, and it isn't a sample from a cubital vein. Concentrations in the long portal vessels are high, pulsatile, and largely cleared before they reach the arm. A peripheral GHRH measurement is therefore a poor photograph of what the somatotroph just heard. Clinical tests that still use GHRH, often with arginine to suppress somatostatin, are provocations: they ask whether the pituitary can still answer, not what the hypothalamus whispered an hour ago. The arcuate GHRH neuron is itself gated. Slow-wave sleep is the largest physiological window. Fasting amplifies. Sex steroids shape amplitude and frequency. Thyroid hormone is permissive for GH synthesis; a hypothyroid somatotroph writes fewer granules. Free fatty acids suppress GH release, one of the reasons abdominal adiposity is a low-GH state. Hyperglycaemia suppresses GH and will blunt a GHRH or secretagogue challenge, which is why a fed animal and a fasted animal aren't the same two-key assay. A pair of laboratory analogues arriving from the periphery occupies two receptors in that village. The village is still there when the analogues arrive, and it still has a vote.

In short. The pituitary hears GHRH in a special local blood supply, in bursts, gated by sleep, sugar and fasting. Analogues occupy two receptors in that whole village.

Ghrelin is the third hypothalamic-adjacent speaker, and it isn't hypothalamic in origin for most of its circulating mass. Kojima, Hosoda, Date, Nakazato, Matsuo and Kangawa, Nature 1999: a twenty-eight-residue peptide from the stomach, uniquely octanoylated on serine 3 by ghrelin O-acyltransferase, occupying the receptor that Howard, Smith and colleagues had cloned three years earlier as an orphan growth-hormone secretagogue receptor. The acylation is obligatory for GHS-R1a agonism. Des-acyl ghrelin circulates in larger amounts and is a different conversation. At the pituitary, GHS-R1a is expressed on somatotrophs and synergises with GHRH. In the arcuate, the same receptor sits on NPY/AgRP neurons and is the reason ghrelin is an orexigenic signal as well as a secretagogue. Vagal afferents carry a third copy of the story. One ligand, several addresses, one G protein family. A catalogue pentapeptide that occupies GHS-R1a will inherit that geography whether a protocol only sampled GH or not. Modified GRF(1–29) doesn't occupy that receptor. It occupies GHRHR. The two ligands are how you isolate the two locks, and how you occupy them together without pretending they are one substance.

In short. Ghrelin is a stomach hormone with a fat chain on one serine. It raises growth hormone and also talks to hunger circuits. The GHRH analogue does not occupy that receptor.

Genetic proofs keep the cascade in order, which is why they belong here and not only in a textbook. The little mouse carries a missense mutation in Ghrhr; it's GH-deficient and small, and it's why Mayo's clone of the receptor was more than a sequence on a gel. Human isolated GH deficiency type IB includes GHRHR mutations, particularly in consanguineous cohorts that paediatric endocrinology still cites. Laron syndrome is the next floor down: GHR mutations, high GH, very low IGF-1, a receptor that won't rotate and won't recruit JAK2. A GHRH analogue can't rescue Laron. A ghrelin-receptor agonist can't rescue it either, because both ligands ask the somatotroph, and Laron's break is one floor further on. A GH analogue can't rescue a missing STAT5b. Mecasermin, recombinant native IGF-1, is the licensed ligand when the cascade is broken below GHR, in a named paediatric indication. Occupying GHRHR and GHS-R1a is a precise pair of questions. It's a useless pair if the somatotroph, or the GH receptor, or STAT5b, is the floor that actually failed. That's the genetics doing what genetics does: telling you which lock you actually have.

In short. Mutations show the cascade is ordered: these two receptors, then growth hormone, then IGF-1. Neither analogue can fix a break at a floor it never reaches.

GHRHR is a class-B secretin-family GPCR, the same structural neighbourhood as GLP-1R, GIPR, GCGR and the secretin receptor itself. Seven transmembrane helices, a large N-terminal extracellular domain that captures the C-terminal half of the peptide, and a transmembrane pocket that reads the N-terminus. Occupancy rearranges the helices. The intracellular face becomes a guanine-nucleotide exchange factor for Gs. Mayo cloned the receptor in the early 1990s; Molecular Endocrinology, 1992. Inactivating mutations cause a rare isolated growth-hormone deficiency, which is the genetic proof that this protein isn't optional in the axis. Class B is a different extracellular architecture from the rhodopsin-like class A that GHS-R1a belongs to. A chemist who designs a GHRH analogue is designing against a hormone-binding ectodomain, not against a small-molecule cleft. That's why the first twenty-nine residues still matter, and why a five-residue ghrelin-receptor agonist can't be filed as a short GHRH. Two locks. Two ligand lengths. One granule downstream, if both locks turn. Treat 'growth-hormone peptide' as one substance and you've already mixed those objects, and you'll misread both a certificate of analysis and a pituitary-slice paper that applied them together.

In short. The GHRH receptor is a seven-helix protein in the same family as the gut-hormone receptors. Occupying it loads a stimulatory G protein called Gs.

Gs is the first amplifier. GTP-bound Gαs occupies adenylyl cyclase. Cyclic AMP rises, in somatotrophs, by enough to occupy protein kinase A. PKA phosphorylates CREB, which is the transcriptional half of a longer GHRH exposure, and phosphorylates the machinery that opens L-type voltage-gated calcium channels. Calcium enters. Local calcium at the granule is the proximate trigger for exocytosis of stored growth hormone. The granule is a dense-core vesicle packed with GH, already synthesised, waiting. A pulse, on the seconds-to-minutes clock, is mostly that fusion event. Hours of GHRH tone will also write more GH gene transcription via Pit-1, more granules, a larger readily-releasable pool. Two clocks, one receptor. A short-acting analogue asks the first clock. An albumin-conjugated analogue asks both, and then asks what the liver does with a flattened GH tone, which is a third question. Cyclic AMP is hydrolysed by phosphodiesterases. Somatostatin, via Gi, opposes the cyclase. The pulse is therefore a contest at the cyclase as well as a contest at the portal, and a second G protein arriving through GHS-R1a is a second vote on that same contest rather than a new hormone axis invented for the occasion.

In short. GHRH raises a messenger called cAMP, which opens calcium channels so stored growth hormone can be released. A short analogue asks that quick release.

L-type calcium current is the sentence most summaries skip, and it's the sentence that makes the two-key experiment intelligible. Somatotrophs are electrically excitable. They fire action potentials. The depolarisation that GHRH and ghrelin both encourage, by different G proteins, opens Cav1 channels. The calcium that enters is the fusion signal. Block those channels with a dihydropyridine in a pituitary slice and the GH pulse collapses, which is old pharmacology and still a useful control if someone claims a GHRH analogue or a secretagogue released hormone by a novel inner path. GHRH gets there through cyclic AMP and PKA. Ghrelin gets there through Gq, phospholipase C, IP3, and a rise in intracellular calcium that also depolarises. The two paths converge on the same granule. That convergence is why co-application of a GHRH analogue and a GHS-R1a agonist releases more GH than either ligand alone, in slices and in animals, and why textbooks draw the large pulses as a combination. Synergy is a G-protein fact. Isolating each ligand is how you know which receptor did the work. Naming both concentrations is the standard the pituitary-slice papers already set, and it's a rather satisfying one once you see it.

In short. Both GHRH and ghrelin raise calcium inside the pituitary cell, by different routes, and growth-hormone granules then fuse. Together they make the large bursts.

Desensitisation is why more ligand isn't more signal forever, and it's one of the costs an albumin-conjugated analogue buys when it buys duration. Occupied GHRHR is phosphorylated by GRKs, binds β-arrestin, and is internalised. Recycle or degrade, depending on the duration and the cell. A somatotroph that sees continuous GHRH tone will, within hours, present fewer receptors and a smaller cyclic-AMP increment per molecule of ligand. That's ordinary GPCR biology, the same arithmetic Lefkowitz spent a career on, applied to a class-B receptor whose ligand in life is a pulse. Tesamorelin, dosed once daily as a licensed medicine, lives with that trade because its indication asked for a sustained IGF-1 rise and a visceral-fat readout, not a copy of nocturnal physiology. A research analogue without DAC was built for the other trade: occupy, raise cyclic AMP, open the calcium current, fuse granules, and then get out of the way so the receptor census and the trough can recover. Getting out of the way is a pharmacokinetic property. It's also a scientific decision, and it's the decision that makes a two-key pulse possible rather than a two-key drip.

In short. If GHRH stays high for too long, the receptor is pulled inside and the cell hears less. A short analogue leaves so hearing can recover.

Howard, Smith and colleagues cloned the secretagogue receptor in 1996. Science, 273: 974–977: a receptor in pituitary and hypothalamus that functions in growth-hormone release. GHS-R, growth-hormone secretagogue receptor, an orphan class-A GPCR with two splice forms. GHS-R1a is the seven-helix functional receptor. GHS-R1b is a truncated five-helix variant that doesn't signal as a GH secretagogue receptor on its own and has been argued over as a modulator ever since. The clone explained the hexapeptides Bowers had been making since the 1980s. It didn't clean them. Ligands that had been dirty on ACTH before the clone were still dirty on ACTH after the clone, because the off-axis pharmacology was a property of those chains at those concentrations, not a property of ignorance about the sequence. Naming the target is necessary. It isn't sufficient. Cite Howard 1996 and then use GHRP-6 as if the clone had subtracted the prolactin, and you're citing a paper you haven't allowed to change the protocol. Ipamorelin is the pentapeptide that did change the protocol. The clone told you where it sits. Raun's tables told you what else it doesn't sit on.

In short. The ghrelin receptor was cloned in 1996 as an orphan that released growth hormone. Putting a name on the lock did not make the older keys any cleaner.

Kojima, Hosoda, Date, Nakazato, Matsuo and Kangawa, Nature 1999, 402: 656–660, found the endogenous ligand three years later. Ghrelin: a twenty-eight-residue peptide from the stomach, uniquely octanoylated on serine 3. The acylation is obligatory for GHS-R1a agonism. Ghrelin O-acyltransferase, GOAT, installs that lipid in the stomach, a post-translational modification so unusual that the isolation paper had to argue for it. Des-acyl ghrelin circulates in larger amounts and is a different conversation: it doesn't occupy GHS-R1a as the acylated peptide does, and papers that treat total ghrelin as the agonist are measuring a mixture. Synthetic growth-hormone secretagogues don't need that octanoyl, because they were built against the orphan rather than copied from the stomach. Ipamorelin is one of those synthetic peptides. It isn't ghrelin. It doesn't carry a serine-3 lipid. It doesn't share ghrelin's twenty-eight-residue backbone, ghrelin's GOAT dependence, or ghrelin's circulating des-acyl majority species. It occupies the same class-A receptor, raises calcium by the same Gq-first route, and inherits the geography of that receptor whether a protocol only sampled GH or not. The distinction is chemistry, and it's worth keeping in your pocket.

In short. Ghrelin is a twenty-eight-amino-acid stomach hormone with a fat chain on one serine. Ipamorelin occupies the same receptor but is not that hormone.

GHS-R1a is a class-A GPCR, rhodopsin-like, with a high constitutive activity that the field has argued about since the clone. The dominant coupling is Gq/11: phospholipase C, PIP2 cleavage, IP3, a calcium rise from stores and from the plasma membrane. A Gi component is real and is part of why the electrophysiology of a somatotroph seeing ghrelin isn't a carbon copy of one seeing GHRH. β-arrestin is recruited; biased ligands exist in the medicinal-chemistry literature and aren't this catalogue. Synergy with GHRH is the physiological point of GHS-R1a on the somatotroph. In hypothalamic–pituitary clamp experiments, a GHRH pulse in the presence of a secretagogue produces a much larger GH burst than GHRH alone; a secretagogue in the absence of GHRH produces a smaller one. The large nocturnal pulses that Veldhuis deconvolved are, on this picture, a GHRH event amplified by ghrelin tone and permitted by a somatostatin trough. Two receptors, two G proteins, one granule. That's why co-application is how pituitary slices release the large pulses textbooks draw, and why applying both ligands means naming both concentrations.

In short. The ghrelin receptor raises calcium by a different G protein from GHRH. When both receptors are on, the pituitary burst is larger than either signal alone.

Receptor geography is the sentence a GH-only assay will try to skip, and it shouldn't be allowed to. GHS-R1a is expressed on somatotrophs, which is why a secretagogue raises GH. It's expressed in the arcuate on NPY/AgRP neurons, which is why ghrelin is hunger as well as hormone. It's expressed on vagal afferents, which is why some of the gastric and appetite story is a nerve rather than a pituitary. It's expressed in the enteric nervous system, which is why a later clinical programme could even ask about postoperative ileus. Cardiac and bone addresses exist in the literature and are real enough that a sentence saying 'GH secretagogue' was never only a GH sentence. A catalogue pentapeptide that occupies GHS-R1a will inherit that geography. Modified GRF(1–29) will not, because it occupies GHRHR, a pituitary-predominant class-B receptor without that hunger map. The two ligands are how you isolate the two locks. Pretend the pentapeptide is a pituitary-only tool and a clean GH table becomes a confused feeding study. Pretend the pair is a single growth slider and both geographies, and both G proteins, disappear into a blend.

In short. The ghrelin receptor also sits on hunger circuits and on nerves from the gut. The GHRH receptor does not. Using both ligands means inheriting both maps.

Cyril Bowers spent the 1980s making smaller, stronger peptides that released GH from pituitary cells without being GHRH. That was a genuine surprise, and you can still feel it in the papers. The hypothalamic go peptide was already on the table, isolated in 1982; a hexapeptide that released GH by a different route implied a second receptor the textbooks hadn't drawn. GHRP-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, worked. It released GH from rat pituitary cells, from animals, later from people. It also moved ACTH, cortisol and prolactin, which is a messy experiment if the question was isolated growth-hormone release. Hexarelin, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, did the same circus with more potency. GHRP-2 sat in the same family. The field had ligands and no clone. Medicinal chemistry ran ahead of molecular biology, which isn't rare and is how you end up with a drawer of hexapeptides that occupy a protein you can't yet name. The drawer was useful. It was also dirty on the stress axis, and nobody should have pretended otherwise. The later clone, and then Raun's pentapeptide, are how the drawer got a labelled lock and a cleaner key. Bowers' synergy papers are why the drawer still matters.

In short. In the 1980s chemists found short peptides that released growth hormone without being GHRH. They worked, and they also shoved stress hormones around.

Bowers' synergy observation is the reason anyone can say the word pair in a laboratory without wincing. Give GHRH alone, you get a pulse. Give a growth-hormone-releasing peptide alone, you get a pulse that still wants GHRH tone in the background. Give both, and the output is super-additive, not because the peptides are magic together, but because cyclic AMP and calcium are. GHRHR raises cyclic AMP through Gs; PKA phosphorylates L-type calcium channels; calcium enters; granules fuse. GHS-R1a raises calcium through Gq, phospholipase C and IP3, from stores and through a depolarisation that also opens those L-type channels, with a Gi component that redraws somatotroph excitability. Both paths meet at exocytosis of the same dense-core granule. Somatostatin, via Gi, leans on the cyclase the other way. Two second-messenger systems on one secretory machine is a sentence from cell physiology, not from a shopping list. The papers that combined GHRH and a secretagogue in pituitary slices named both receptors and both doses. That's the standard. Recapitulating the large pulse the textbooks draw is lawful. Recapitulating it without naming both concentrations is how a G-protein fact becomes a blend.

In short. A GHRH analogue plus a ghrelin mimetic releases more growth hormone than the two signals added up, because two internal messengers land on the same granule.

Clamp experiments made the dependence visible, which is why they belong here rather than only in a footnote. A GHRH pulse in the presence of a secretagogue produces a much larger GH burst than GHRH alone. A secretagogue in the absence of GHRH produces a smaller one. Passive immunisation against GHRH, or a GHRHR antagonist, blunt the secretagogue response; the second lock still wants the first lock's tone. Somatostatin infusion, or a somatostatin analogue, blunts both, because Gi is still the stop. Fasting, which raises ghrelin and drops somatostatin tone, amplifies a GHRH challenge. Hyperglycaemia, which does the reverse, blunts it. Those gates are why a clean pair of ligands still isn't a push-button, and why the metabolic state of the animal is part of the two-key experiment rather than a nuisance variable you forgot to write down. Bowers described the pair as more than additive. Veldhuis described the product as a digital signal. The two sentences are the same physiology at two scales: second messengers on a granule, then bursts in plasma. Flatten either scale and you've changed the ligand even if the sequences are identical.

In short. The large burst needs GHRH tone, a ghrelin-receptor push, and a drop in the stop signal. Sugar, fasting and sleep all change that mix.

Super-additivity is a number, and the number has to be earned. If ligand A releases X and ligand B releases Y, A plus B releasing something near X plus Y is additivity, which is already a useful co-application. Releasing more than X plus Y is synergy, which is the claim Bowers made and which later slice and in-vivo work supported at GHRHR plus GHS-R1a. The mechanism is convergence, not a mysterious third receptor. Cyclic AMP from Gs and calcium from Gq land on the same exocytotic machinery; each increment makes the other more effective at fusing granules that were already packed. That's why the pair can look stronger than a larger dose of either ligand, and why turning up one ligand to compensate for the absence of the other is a different experiment from occupying both. It's also why a dirty secretagogue confounds the arithmetic: extra ACTH and cortisol change the hepatic programme you thought you were reading as an IGF-1 effect of the GH burst. Raun's pentapeptide is how you keep the arithmetic about G proteins rather than about the stress axis. Bowers gave you the pair. Raun gave you a cleaner second key.

In short. True synergy means the pair beats the sum of the parts, because the two messengers help each other at the granule. A noisy second key scrambles that sum.

Somatostatin remains the third input, and experiments that occupy two ons and pretend the off has left the building are how this axis got a muddled reputation. Periventricular somatostatin neurons set a high interpulse tone. A physiological pulse is GHRH up, somatostatin down, ghrelin as amplifier. A laboratory pair arriving from the periphery raises the two ons without a guaranteed drop in the stop. Arginine, used in clinical GHRH tests, is there partly to suppress somatostatin so the pituitary can actually answer. Hexarelin and some older GHRPs have been argued to inhibit somatostatin as well as occupy GHS-R1a, which would make their 'synergy' a three-receptor event wearing a two-receptor label. Ipamorelin wasn't built as a somatostatin antagonist. Modified GRF(1–29) wasn't built as one either. A two-key assay that wants GHRHR plus GHS-R1a still has SSTR2/5 in the background, because physiology didn't leave. Measure the stop, or at least name it. Occupying two inputs is a design choice in an assay. Ignoring the third is a design failure, and it's an easy one to make if you fall in love with the pair.

In short. The stop signal is still there when you occupy both on-switches. A real pulse is two ons plus a drop in the off, not two ons on their own.

Native GHRH is forty-four residues, and GRF(1–29)-NH2 is the truncation that built every laboratory analogue that matters. Take the first twenty-nine residues of the forty-four, amidate the new C-terminus, and the class-B receptor still sees full agonism. The C-terminal fifteen residues of native GHRH contribute to binding and to circulating half-life in some assays; they aren't required for efficacy at GHRHR. That's a structural fact about a secretin-family receptor, not a marketing convenience. The large N-terminal extracellular domain of GHRHR catches the C-terminal half of a longer peptide; the transmembrane bundle reads the N-terminus, which is why chopping the N-terminus makes an antagonist and chopping the far C-terminus does not. Modified GRF(1–29) sits on that twenty-nine-residue backbone. Tesamorelin, the licensed neighbour, sits on the full forty-four with a hexenoyl cap. Two lengths, one receptor family, two design decisions. Treat 'GHRH analogue' as one substance and you've already mixed those objects, and you'll misread both a certificate of analysis and a package insert. In a two-key experiment the GHRH microphone has to be named as a length and as a clock, not as a family nickname.

In short. The first twenty-nine amino acids of GHRH are enough to switch the pituitary receptor fully on. That shorter chain is the backbone of the pulse-length analogue.

Dipeptidyl peptidase-IV is a serine protease on endothelial cells and in plasma that removes two N-terminal residues from peptides with a proline or alanine in the second position. Native GHRH has alanine at position 2 and aspartic acid at position 3. The enzyme cleaves that Ala2–Asp3 bond within minutes in plasma. The truncated product doesn't occupy GHRHR as an agonist. That's why a forty-four-residue hypothalamic peptide, potent at the receptor, is almost useless as a peripheral ligand: the journey from a syringe to a somatotroph is long enough for DPP-IV to finish the job. Mentlein and colleagues mapped this cleavage family in the 1990s on incretins; the same enzyme is why native GLP-1 dies in about two minutes and why sitagliptin exists. GHRH and GLP-1 aren't the same hormone. They share an enemy. Talk about 'boosting GHRH' without saying whether you mean the enzyme, the receptor, or a substituted analogue, and you haven't chosen a mechanism. The analogue in this page chose the receptor, and chose to survive the enzyme by substitution rather than by inhibiting it. D-Ala2 is that substitution, and it's a rather elegant one.

In short. An enzyme in blood called DPP-IV cuts native GHRH in minutes and turns it off. Chemists changed the second amino acid so the analogue can last a burst.

D-Ala2, Gln8, Ala15 and Leu27 are the four substitutions, and each earns a named sentence. Replacing L-alanine at position 2 with its D-enantiomer removes the scissile bond DPP-IV wants. The enzyme is stereoselective; a D-residue at P1 is a locked door. Position 8 in native GRF is asparagine; asparagine rearranges and deamidates, a slow chemical death you'll meet if you leave a reconstituted native sequence on the bench. Glutamine at 8 reduces that rearrangement. Position 15 is glycine in the native twenty-nine-mer; alanine there stabilises a helical stretch that the receptor likes. Position 27 is methionine in the native chain; methionine oxidises, and oxidation is how a perfectly synthesised peptide becomes a mixture after air and time. Leucine at 27 removes that sulphur. Four edits, four liabilities, one backbone that still occupies GHRHR with full efficacy. That tetrasubstituted peptide is what the trade calls mod GRF 1–29, and what a catalogue files as CJC-1295 without DAC. The sequence is the product. The absence of the maleimide is the other half of the product. Tens of minutes is still a pulse on a somatotroph's clock, and that's the point.

In short. Four amino-acid swaps stop the chain being cut, unfolding, deamidating or oxidising. After those swaps it lasts tens of minutes, which is still a burst.

DAC is Drug Affinity Complex, ConjuChem's covalent half-life trick. The chemistry is an N-ε-maleimidopropionyl-lysine on a GHRH-analogue backbone. The maleimide Michael-adds to cysteine 34 of circulating albumin, a free thiol that peptide chemists have been aiming at for decades because albumin's own half-life is measured in weeks. Once conjugated, the peptide rides albumin for days. Clearance slows. Occupancy at GHRHR never quite returns to a trough. The original branded CJC-1295 was this conjugate. Papers that say CJC-1295 and mean the ConjuChem molecule are talking about the albumin adduct, not about tetrasubstituted GRF(1–29) sitting free in plasma. The trade then started selling the unconjugated tetrasubstituted twenty-nine-mer as CJC-1295 without DAC, which is how a catalogue ends up with a name that is a negation. The negation is the scientific sentence. Without the maleimide, modified GRF(1–29) remains a short-acting GHRH analogue that can still pulse. That's the version a two-key experiment wants, because the second key is itself pulse-length, and pairing a pulse with a drip is how you accidentally run Teichman's question when you thought you were running Bowers'.

In short. DAC is a chemical hook that glues the peptide to blood protein for days. Without that hook, the analogue stays short-acting. That absence is the point.

Teichman, Neale, Lawrence, Gagnon, Castaigne and Frohman, Journal of Clinical Endocrinology and Metabolism, 2006, 91: 799–805, is the paper the conjugate owes you. A single subcutaneous dose of CJC-1295 with DAC produced multi-day elevation of GH and of IGF-1 in healthy adults. The tone was continuous rather than pulsatile. IGF-1 stayed up. That's a real result, in people, with a characterised albumin-conjugating analogue, and it answers the question ConjuChem asked: can you occupy GHRHR for days and move the hepatic integral. You can. The liver wrote IGF-1. What the liver didn't write, because nobody asked it to in that design, is a Veldhuis burst series with troughs. Subsequent clinical development of the conjugate didn't produce a licensed GHRH medicine; tesamorelin, a different analogue, took that job. The 2006 paper remains the existence proof for flattened GHRH tone. It's also the existence proof that flattened tone is a different object from modified GRF(1–29) without the maleimide. A two-key assay that wants Bowers' synergy as a pulse wants the version that still troughs. Pairing ipamorelin with the albumin adduct is a different experiment, with a different clock, and it should be named as one.

In short. A 2006 study showed that the albumin-glued version keeps growth hormone and IGF-1 raised for days after one dose. That is a flattened signal, not a burst.

Ipamorelin is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a pentapeptide agonist at GHS-R1a, the ghrelin receptor. Five residues, a C-terminal amide, two D-amino acids, an aminoisobutyric acid at the N-terminus. Write the sequence in full, because a five-mer has nowhere to hide. Position 1 is aminoisobutyric acid, Aib, a non-proteinogenic residue with two methyls on the alpha carbon, which stalls aminopeptidases. Position 2 is histidine, the same first proteinogenic residue Bowers put on GHRP-6. Position 3 is D-2-naphthylalanine, a bulky aromatic D-amino acid that isn't in the genetic code. Position 4 is D-phenylalanine, another D-aromatic. Position 5 is lysine, amidated at the C-terminus. Molecular weight 711.9. CAS 170851-70-4. The D-residues and the Aib are why plasma proteases have a harder time than they would with an all-L pentapeptide of equivalent mass. Minutes, for a secretagogue, are the useful window: long enough to occupy GHS-R1a through a burst, short enough that a trough can still happen. Ipamorelin wasn't built to last a week. It was built to be a pulse-length ligand at a receptor whose endogenous agonist is itself a short-lived acylated peptide. That clock is why it can sit next to modified GRF(1–29) as a second pulse rather than as a drip.

In short. Ipamorelin is a five-amino-acid key for the ghrelin receptor. Unusual starter chemistry and two mirror-image residues help it last a burst, not a week.

Raun, Hansen, Nielsen, Heinig, Andersen, Thøgersen, Ankersen and Madsen, European Journal of Endocrinology, 1998, 139: 552–561, is the paper this pentapeptide owes you. In vitro, on rat pituitary cells, it released growth hormone. In vivo, in swine and in rats, plasma GH rose. ACTH, cortisol and prolactin did not, at doses that were effective for GH, in contrast to GHRP-6 and hexarelin run in the same protocols. That last clause is the argument, and it's why a bench still reaches for this analogue a quarter of a century later. The dose–response tables are assigned reading because they're how you tell a selective tool from a noisy one. The analogue doesn't meaningfully bind the motilin receptor, a related GPCR that some ghrelin-family ligands graze. Oral bioavailability is poor, as you'd expect for a pentapeptide with those side chains; the papers use parenteral animal protocols or in-vitro work. If you only read one paper on this pentapeptide, make it Raun 1998. The tables are the argument for putting this key on the second lock rather than GHRP-6, and they're still a pleasure to sit with.

In short. A 1998 paper showed this pentapeptide raises growth hormone while leaving stress hormones mostly quiet, unlike the older, noisier ghrelin-receptor peptides.

Early growth-hormone secretagogues occupied GHS-R1a and also moved ACTH and prolactin. Fine if you were cataloguing side-effects. Poor if you wanted GH as the variable. GHRP-6 worked, and the circus came with it. Hexarelin did the same with more potency. When Smith's group cloned GHS-R, those ligands had a named target; they still had the off-axis baggage. The secretagogue field then split into cleaner tools and louder ones. A louder one isn't a better partner for a GHRH analogue. It's a partner plus a cortisol confound that will change the hepatic programme you thought you were reading as an IGF-1 effect. Downstream, that cortisol will antagonise some of the IGF-1 pattern, mobilise glucose, and alter immune readouts. Want isolated GHS-R1a agonism, or isolated GHRHR-plus-GHS-R1a synergy, and you've then measured a mixture. Raun's tables are why ipamorelin is still the cleanest peptide secretagogue to put on a bench, and why it's the second key we'll keep naming. If you wanted GHRHR plus GHS-R1a, you wanted modified GRF(1–29) and ipamorelin, each characterised, each named, each at a stated concentration.

In short. Older ghrelin-receptor peptides also shoved stress hormones around. Extra cortisol scrambles the liver readout you thought was growth hormone, so a clean partner matters.

Selectivity is relative, not absolute, and it's worth saying that without raising your voice. GHS-R1a is still a hunger receptor. It still sits on NPY/AgRP neurons and on vagal afferents. A pentapeptide that occupies it will still have an appetite conversation; Raun subtracted ACTH and prolactin at GH-effective doses, not the geography of the lock. A later Novo Nordisk and Helsinn programme asked whether ipamorelin would recover postoperative ileus. It didn't meet its primary endpoint. That's a useful reminder that a clean GH secretagogue isn't a universal gut drug, even though GHS-R1a is expressed in the enteric nervous system. Receptor geography isn't a licence to generalise the indication, and it isn't a reason to skip the hunger sentence in a two-key write-up. Bring ACTH, cortisol and prolactin to the table if you claim the word selective. Bring a food-intake or emptying readout if you claim the pair is pituitary-only. The two-key experiment is then: modified GRF(1–29) at GHRHR, ipamorelin at GHS-R1a, somatostatin still in the background because physiology didn't leave. Selectivity is how you know which G protein did the work. Geography is how you know which organ you actually asked.

In short. Clean does not mean only the pituitary. The same receptor also talks to hunger. Measure stress hormones and, if you claim a gut effect, measure the gut.

Partner is a dangerous word, which is why we'll keep unpacking it. The two peptides occupy two receptors. Combined, they recapitulate the large pulse the textbooks draw. Combined without naming both concentrations, they become a stack, and a stack is a purchasing habit rather than an experiment. We stock both sequences as named cakes, HPLC-characterised. A blend vial, where it exists, is ten milligrams of each freeze-dried together: two named sequences, two masses, two retention times, a certificate that names both. Logistics for a reading list that already contained two ligands. It's still GHRHR plus GHS-R1a. It's still Bowers' two G proteins on one granule. It isn't a protocol, and it isn't a licence to stop attributing the GH peak. The singles remain on the shelf so you can occupy only GHS-R1a, or only GHRHR, if that's the lock you actually want. Treat the blend as a stronger ipamorelin and you've mixed a class-B Gs ligand with a class-A Gq ligand and called the mixture a dose. Two cakes. Two questions. A reading list can sit them together. A write-up can't collapse them.

In short. The two peptides occupy two receptors. Freeze-drying them in one vial does not make them one ligand, and it is not a recipe.

Johannes Veldhuis spent a career showing that growth hormone is a digital signal. Deconvolution of frequent-sampled plasma GH, in humans and in animals, yields discrete bursts superimposed on a low interpulse baseline. Most of the mass is in the bursts. Most of the bursts, in a healthy adult, cluster after sleep onset, in slow-wave sleep, with a smaller daytime population. Amplitude falls with age, with abdominal adiposity, with hyperglycaemia. Amplitude rises with fasting, with oestradiol in some protocols, with a GHRH or secretagogue challenge. The pattern is the message. A single morning clinic GH is almost uninterpretable without an IGF-1, and even IGF-1 is an integral, not a pulse photograph. The papers sit in Journal of Clinical Endocrinology and Metabolism, in Endocrine Reviews, in a run of American Journal of Physiology pieces that a generation of fellows were handed. Report GH as a continuous infusion or as a daily subcutaneous bolus and then talk as if you'd reproduced physiology, and you haven't read Veldhuis. A two-key pair of pulse-length ligands exists so that reading still has reagents. Flatten the first key with a maleimide and you've already left his deconvolution.

In short. Growth hormone comes in bursts, mostly at night. Veldhuis showed the pattern itself carries the message. A flattened dose is a different signal from a pulse.

Sleep is the largest physiological gate. Slow-wave sleep and the first nocturnal GHRH-permissive window coincide; deprive the slow waves and the GH peak shrinks. That's why night-time sampling exists, and why a daytime secretagogue challenge is a different probe from a nocturnal endogenous pulse. Thyroid hormone is permissive for GH synthesis. Glucocorticoids, in excess, suppress the axis at hypothalamus and pituitary; in replacement they are allowed. Sex steroids shape amplitude and frequency. Free fatty acids suppress GH release. Ghrelin and fasting push the other way. Hyperglycaemia suppresses GH and will blunt a GHRH or secretagogue challenge, which is why a fed animal and a fasted animal aren't the same two-key assay. The somatotroph isn't an isolated oscillator. It's a cell reading a hypothalamic ratio, a metabolic plasma, and a sleep clock. A tetrasubstituted twenty-nine-mer occupies one receptor in that village. A pentapeptide occupies another. Claiming the pair 'is a pulse' without saying what the rest of the village was doing is a half-sentence. Name the metabolic state. Name the clock. Then occupy the two locks. The cell will still be listening to everything else.

In short. Sleep, sugar, fat, thyroid and fasting all gate these bursts. The two analogues occupy two receptors; the rest of the body still has a vote.

Sampling is the unglamorous half of pulsatility, and it's where analogue papers most often cheat. A single clinic GH, drawn at nine in the morning, reports a trough more often than a peak and can't distinguish deficiency from a nadir between bursts. Frequent sampling, every ten or twenty minutes overnight, is how Veldhuis deconvolved mass and frequency; it's also how you prove you've reproduced a pulse rather than an integral. IGF-1 is the integral: a hepatic average over hours, useful, and blind to whether the night was three large bursts or a flattened plateau. IGFBP-3 and the acid-labile subunit are slower integrals still. Occupy GHRHR and GHS-R1a with two thirty-minute analogues and then draw IGF-1 at a week, and you've measured the liver's running mean, not the somatotroph's burst. Draw GH at twenty-minute intervals around the dose if the question is the pulse. Draw IGF-1 if the question is the hepatic programme. Draw ACTH and prolactin if the second key's selectivity is the claim. Name which integral you meant. The clock you choose is part of the ligand, whether you like that sentence or not.

In short. One morning blood test for growth hormone is usually a quiet gap. Frequent samples show bursts. IGF-1 averages hours of liver output and hides those bursts.

Continuous growth hormone isn't pulsatile growth hormone at the liver, which is the design constraint that makes without-DAC a scientific sentence in a two-key assay. Hepatocytes reading a pulsatile STAT5b phosphorylation write IGF1, ALS and IGFBP3, the ternary-complex programme that circulating IGF-1 actually travels in. Hepatocytes reading a flattened GH tone write a different programme: more insulin antagonism, a different lipid-gene set, less of the IGF pattern many protocols thought they wanted. Receptor down-regulation contributes. SOCS2, a STAT5b target, feeds back and shuts the receptor down when occupancy is unrelieved. Jørgensen, the older rodent infusion studies, and the clinical experience with continuous subcutaneous GH pumps all point the same way. In the rat, a three-hour GH infusion and a pair of pulses matched for area-under-the-curve don't write the same cytochrome P450 genes. Pattern is information. Flatten it and you've changed the ligand even if the amino-acid sequence of GH is identical. That sentence is the design constraint for every GHRH analogue, and it's why a two-key experiment that wants Bowers' synergy as physiology stocks the pulse-length ligand rather than the albumin adduct.

In short. The liver reads growth-hormone bursts as one gene programme and a continuous drip as another. Flatten the pulse and you change the message.

Four laboratory analogues sit on four microphones of the same axis, and confusing them is how a journal becomes a stack. Modified GRF(1–29) without DAC asks what a slightly prolonged GHRH pulse does to somatotrophs, to GH burst mass, and to the hepatic STAT5b programme when troughs are still allowed. Ipamorelin asks what selective GHS-R1a agonism does to the same granule, and to arcuate and gastric addresses, without dragging ACTH and prolactin into the table. Combined, they ask Bowers' question with cleaner tools than GHRP-6: two receptors, two G proteins, one pulse, each ligand named. Recombinant somatropin asks the GH receptor itself, skipping the hypothalamus and the pituitary. IGF-1 LR3 bypasses the pituitary and the liver and asks the tyrosine kinase on a myotube or a hepatocyte, with binding proteins taken out of the fight. Four ligands, four receptors, four questions. The axis essay next door is the wiring they share. This page is the two-key version. Confuse the four and you're assembling a stack. Attribution is the job, and it's a kinder job than it sounds: name the lock, and the rest of the sentence writes itself.

In short. Four related peptides ask four different receptors on the same hormone axis. This page is the pair of pituitary on-switches, not the whole set mixed together.

Tesamorelin is a trans-3-hexenoyl GRF(1–44), Egrifta in the United States, licensed for reduction of excess abdominal fat in HIV-associated lipodystrophy. The hexenoyl cap is a different DPP-IV-resistance trick from D-Ala2: an acyl group on the N-terminus rather than a stereochemical swap at position 2. The backbone is the full forty-four rather than twenty-nine. Falutz, Allas, Blot and colleagues ran the trials that earned the indication; New England Journal of Medicine 2007 is the paper most people mean. IGF-1 rose. Visceral adipose tissue fell on imaging. Glucose had to be watched, as you'd expect when you raise GH tone in adults. Daily subcutaneous dosing of a still-relatively-short analogue is closer to a pulse series than a weekly albumin conjugate is, which is why tesamorelin and CJC-with-DAC shouldn't be collapsed into one sentence either. The licensed molecule is the neighbour this page is obliged to name so that a research pair isn't mistaken for it. Same receptor family on one side of the pair. Different backbone, different cap, different legal class, different fridge. Existence proof that GHRHR is drug-able. Not a label that transfers onto modified GRF(1–29), and not a label that transfers onto a blend.

In short. Tesamorelin is a licensed GHRH medicine for a specific fat-distribution problem in HIV. It proves the receptor can be a drug. It is not this research pair.

Somatropin as a comparison has a flattening problem of its own, even without a secretagogue in the well. A daily subcutaneous bolus of recombinant GH doesn't reproduce nocturnal pulsatility. It produces a broad plasma peak and a long tail, a pattern closer to a drip than to a Veldhuis burst, and the liver notices. Children with GH deficiency still grow on that regimen, which is one of the cleaner endocrine success stories of the late twentieth century, because a growing epiphysis will accept a flattened IGF-1 rise. Adults with true deficiency shift composition on it. Healthy adults given the same flattened signal are a different population, and acromegaly remains the experiment of nature for what chronic excess does to soft tissue, insulin sensitivity and myocardium. The research 191-mer is the ligand those programmes used. Occupying GHR skips the gate this pair lives at. If the question needs a pulse generated by the somatotroph, with somatostatin still in the contest and both on-receptors named, the pulse-length GHRH analogue and the selective pentapeptide are the microphones, not a larger IU count of somatropin. Downstream is a different floor. Name the floor, and the comparison stops being a muddle.

In short. Injected growth hormone talks to a different receptor and arrives as a broad peak, not a night burst. If the pituitary must stay in charge, these two analogues are the tools.

IGF-1 LR3 is the other neighbour people drag into a GHRH-and-secretagogue sentence, and it belongs one floor further down. Francis, McDougall, Bagley, Ballard and colleagues made Long Arg3 IGF-1 by substituting Glu3 for arginine and adding a thirteen-residue N-terminal extension. IGF-binding-protein affinity collapses. IGF1R agonism remains. In serum-containing culture the analogue is the ligand the myoblast actually sees. It doesn't occupy GHRHR. It doesn't occupy GHS-R1a. It doesn't occupy GHR. It occupies a receptor tyrosine kinase, and glucose belongs in that protocol because hybrid insulin receptors are real. Reconstitute modified GRF(1–29), ipamorelin and LR3 into one experiment and you've mixed a class-B GPCR and a class-A GPCR on a somatotroph with an RTK on a myotube. Lawful, if all three questions are named. Unlawful as attribution, if a single waist measurement is then credited to 'the GH axis'. The 83-mer has its own essay. The 191-mer has its own. This page is only the two-key version. Walk GHRH and ghrelin to GH to IGF-1, in that order, if the axis is the object. Skip to the kinase if the kinase is the object. Write which skip you made.

In short. A lab form of IGF-1 talks to a different receptor on muscle and other cells. It is not a GHRH analogue, not a ghrelin mimetic, and it does not answer the same question.

What occupying both lets you ask is then precise, which is the only reason to occupy both. What does a slightly prolonged GHRH pulse do to burst mass when a selective GHS-R1a agonist is also present, at stated concentrations, with somatostatin tone named or at least not pretended away. What does isolated GHS-R1a agonism do to the same granule when GHRH is present, and when it is absent, so the synergy can be seen rather than assumed. What does the pair do to gastric emptying and to arcuate NPY neurons without a cortisol confound, which is why the second key is ipamorelin rather than GHRP-6. Those are experiments. A stacking partner isn't an experiment. Sample GH frequently enough to see a burst rather than an integral. Sample ACTH so the selectivity claim survives the combination. Metabolic state of the animal, because glucose and fasting gate the somatotroph. The papers that combined GHRH and a secretagogue in pituitary slices named both receptors and both doses. That's the standard a two-key write-up is expected to meet, and it's a standard you can actually enjoy meeting once the two locks are named.

In short. Using both ligands is an experiment with two named concentrations, frequent growth-hormone samples, and a stress-hormone line. It is not a purchasing habit.

A dish isn't a somatotroph in a sleeping human, and a somatotroph in a sleeping human isn't a hepatocyte, and a hepatocyte isn't an NPY neuron. Species is a variable. Concentration is a variable: nanomolar in a well isn't a plasma free-fraction after proteases, first-pass and dilution have had their turn. Route is a variable: in vitro, intravenous, subcutaneous. DPP-IV will still try to eat an unmodified GHRH even in a tube if plasma is present, which is why the D-alanine isn't optional in any protocol that pretends to be using this GHRH analogue. The pentapeptide's main enemy isn't DPP-IV — it isn't a GHRH backbone with an Ala2–Asp3 bond — but plasma peptidases still exist, and a time course still has to be written. The pulse-length GHRH analogue is how you isolate the GHRHR floor. The pentapeptide is how you isolate the GHS-R1a floor. Together they isolate the two-input device a somatotroph actually is. Apply the pair and measure GH, then IGF-1, then a composition or emptying endpoint, and you've walked the floors. Apply four analogues at once and measure a waist, and you haven't.

In short. A cell dish, a rat and a person are three different systems. Use the two analogues to isolate two receptors, then measure the next step down, in order.

And the messy bit, because there always is one: we don't have a tidy human trial that isolates Bowers' synergy with exactly these two analogues, at research-grade purity, with somatostatin tone measured, with Veldhuis-grade sampling, with ACTH on the same table. The receptor logic is solid. The second messengers converge. The animal and slice literature is real. Translating that into a protocol-shaped object is how this literature got noisy, and it's how a page that only cheers becomes a cartoon. Occupying two inputs is a design choice in an assay. It isn't a human dosing sheet, and it isn't a reason to treat a freeze-dried pair as a medicine. Tesamorelin remains the licensed GHRH analogue in its indication. Recombinant somatropin remains a medicine in diagnosed deficiency. Anamorelin remains a different, non-peptide GHS-R1a ligand with its own trial file. Modified GRF(1–29) without DAC and ipamorelin remain characterised ligands for GHRHR and GHS-R1a, pulse-length by design, sitting on two receptors whose physiology was worked out before any of us were stocking them. The gap between that physiology and a tidy human pair-trial is a fact. Write it down. Then design the experiment you actually have the controls for.

In short. The two-receptor logic is solid in cells and animals. A neat human trial of exactly this pair, with proper sampling, is not sitting on the shelf.

Sequence identity is the honest link between a catalogue vial and a paper, and it's the honest link between two vials and a synergy claim. Modified GRF(1–29) without DAC is a defined tetrasubstituted twenty-nine-mer. Ipamorelin is Aib-His-D-2-Nal-D-Phe-Lys-NH2. HPLC and mass spectrometry are how we know those chains are in the cakes, and how you know the maleimide is absent from the first. A certificate that can't show a main peak and a mass isn't yet a microphone; it's a rumour about a white powder. A certificate that can't show two, when two were claimed, is a rumour about a pair. The kit in the box is bacteriostatic water and syringes so reconstitution is a documented step rather than an argument. None of that is a protocol for combining the two analogues with somatropin or with IGF-1 LR3. It's the minimum a research reagent owes a write-up that will have to put two concentrations on the page. Same sequences as the papers name, characterised, sitting on a shelf because GHRHR and GHS-R1a are named proteins. Confirm the masses. Then run the assay you can actually name.

In short. Each vial is a named chain, checked by chromatography and mass. That identity is what lets a laboratory paper cite a pair honestly.

The two-key sentence, written out at the length it needs, is this. Somatotrophs have two go receptors: GHRHR, a class-B GPCR coupled to Gs–cAMP–PKA and L-type calcium influx, and GHS-R1a, a class-A GPCR coupled primarily to Gq/11 — phospholipase C, IP3, calcium — with a Gi component. Somatostatin is the off-switch at SSTR2/5. Bowers showed that a GHRH analogue plus a ghrelin mimetic releases more GH than the sum of either, because two second-messenger systems converge on one secretory machine. Native GHRH is forty-four residues; GRF(1–29)-NH2 retains full agonism; DPP-IV cleaves Ala2–Asp3 in minutes. Modified GRF 1–29, D-Ala2, Gln8, Ala15, Leu27, lasts tens of minutes and still pulses. The DAC version conjugates to albumin Cys34 and flattens the pulse into days; Teichman 2006 is that object. Ipamorelin occupies GHS-R1a with little of the ACTH and prolactin drag that GHRP-6 carried; Raun, European Journal of Endocrinology 1998, 139: 552–561. Veldhuis: GH is a digital signal. Pattern is information at the liver. Tesamorelin is the licensed GHRH neighbour. Those sentences are the molecular field we were asked to keep. Two keys. One granule. A stop still in the background. That's a pair you can actually hold in your head.

In short. Two pituitary on-switches, one off-switch, a short GHRH analogue that still bursts, a clean ghrelin-receptor pentapeptide, and a liver that reads the pattern.

The neighbouring essays take the rest of the map. The growth-hormone axis, properly explained: four microphones, four questions, the wiring this pair sits on. CJC-1295 without DAC: why the maleimide is absent, why tesamorelin is the licensed GHRH neighbour, why tens of minutes is a scientific number rather than a compromise. Ipamorelin: Raun's tables, the pentapeptide sequence, the failed ileus programme as a reminder that selectivity isn't a universal drug. Somatropin: the 191, JAK2–STAT5b, adult-GHD composition trials, acromegaly as caution. IGF-1 LR3: the 83-mer, the Arg3 substitution, the dish that actually sees the kinase. How peptides talk to cells: occupancy, amplification, arrestin, the class-B and class-A distinction this pair uses on two sides of a synergy. Read those if you're holding a different vial, or if you wanted one microphone rather than two. Stay here if you wanted to know why Bowers' additivity-plus is a receptor fact, why the maleimide is absent from the first key, and why occupying two inputs is a design choice rather than a blended drink. The figure is an organism-level readout. The two receptors are early.

In short. Other essays cover each analogue and the full hormone axis. This one is why the two pituitary on-switches belong in the same sentence, as two named locks.

Research-use-only. Not for human consumption / not a medicine. The lyophilised modified GRF(1–29) without DAC and the lyophilised ipamorelin on these listings are laboratory reagents, HPLC-characterised, labelled for in-vitro work and for the animal protocols a laboratory already knows how to write: a pituitary-cell GH assay, a two-receptor co-application whose concentrations you actually name, a secretagogue challenge whose ACTH line you actually draw. The physiology in the paragraphs above is public, cited, and older than the vials. Use it to design the experiment you have the controls for, with both receptors named, both comparators named, somatostatin not pretended away, and the time point written down. Read Bowers, read Raun, read Veldhuis, read Teichman so you know which clock you didn't pick, then weigh the cakes. We'll sell you the two sequences. We won't tell you they are one ligand, and we won't tell you they are a recipe. Two keys. One granule. The stop still in the background. That's a pair of research chemicals for a named question, with chromatograms on the bench beside them.

In short. The vials are research chemicals for experiments, not a medicine and not a recipe. Weigh both, name both receptors, and keep the claim the size of the tables.